The anti-inflammatory and neuroprotective properties of KCa3.1 blockers have been demonstrated in many animal models, including traumatic brain injury, retinal ganglion cell degeneration, and multiple sclerosis (Mauler et al., 2004; Reich et al., 2005; Kaushal et al., 2007; Yi et al., 2016b). The gene discussed is KCNN4; the disease is multiple sclerosis.